0
Pulmonary Vascular Disease |

Bosentan Improves the Functional Status of Patients With Pulmonary Hypertension Due to Valvular Heart Disease

Georgios Vlachogeorgos, PhD; Irene Kourbeti, PhD; Nicholaos Daskalopoulos, PhD; Panayiotis Blatsiotis, PhD; Ioannis Mantas, PhD; Georgios Stathopoulos, PhD
Author and Funding Information

General Hospital of Chalkida, Chalkida, Greece


Chest. 2013;144(4_MeetingAbstracts):875A. doi:10.1378/chest.1667613
Text Size: A A A
Published online

Abstract

SESSION TITLE: Pulmonary Hypertension

SESSION TYPE: Original Investigation Slide

PRESENTED ON: Monday, October 28, 2013 at 01:45 PM - 03:15 PM

PURPOSE: Vasoconstrictive endothelin signaling has been implicated in pulmonary hypertension due to valvular heart disease. The efficacy and safety of endothelin receptor antagonists in this subpopulation is unknown. In this prospective pilot study we investigated the effects of bosentan in patients with pulmonary hypertension due to rheumatic fever-associated mitral stenosis

METHODS: This was a prospective, single center, open-label, uncontrolled study of regular-dosed oral bosentan in outpatients with pulmonary hypertension (PH) due to rheumatic fever-associated uncorrected mitral stenosis. Primary end-point was exercise capacity at six months as demonstrated by the six-minute walking test (6MWD) and maximal oxygen uptake (VO2max). Secondary end-points were BORG Dyspnea Index (BDI), echocardiographic left ventricular ejection fraction (LVEF), pulmonary arterial pressure (PAP), serum pro-brain natriuretic peptide (pro-BNP) and adverse events.

RESULTS: Ten patients (80% females) with a mean age of 75 were enrolled. Bosentan was well tolerated by nine; one withdrew within a month due to subjective clinical deterioration. By intention-to-treat analysis, bosentan resulted in marked increase in 6MWD test (p=0.015) but a significant reduction in VO2max (-0.45 ml/min/kg; p=0.011). Peak PAP did not change considerably but mean PAP dropped by -16% (p=0.03) and LVEF increased by 6.5% (p=0.003). Importantly, profound reductions were observed in BDI and serum pro-BNP (-67% and -37%; P=0.002 and P=0.011, respectively). Adverse events included minor reductions in body mass and hemoglobin.

CONCLUSIONS: Endothelin receptor antagonism with bosentan appears to improve the functional status of patients with pulmonary hypertension due to valvular heart disease. The beneficial effect was reflected by the improvement in 6MWD test, a superior outcome measurement as determined by the pre-existing literature on PH. The drug was safe and well-tolerated by the patients.

CLINICAL IMPLICATIONS: This study suggests that- pending randomized controlled trials- bosentan and other similar drugs, may prove beneficial in patients with PH due to left heart valvular disease

DISCLOSURE: The following authors have nothing to disclose: Georgios Vlachogeorgos, Irene Kourbeti, Nicholaos Daskalopoulos, Panayiotis Blatsiotis, Ioannis Mantas, Georgios Stathopoulos

No Product/Research Disclosure Information


Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Figures

Tables

References

NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Some tools below are only available to our subscribers or users with an online account.

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Related Content

Customize your page view by dragging & repositioning the boxes below.

Find Similar Articles
CHEST Journal Articles
PubMed Articles
  • CHEST Journal
    Print ISSN: 0012-3692
    Online ISSN: 1931-3543